Unknown

Dataset Information

0

Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against ?1-Adrenergic Receptors.


ABSTRACT: BACKGROUND:Among various cardiac autoantibodies (AAbs), those recognizing the ?1-adrenergic receptor (?1AR) demonstrate agonist-like effects and induce myocardial damage that can be reversed by ?-blockers and immunoglobulin G3 (IgG3) immunoadsorption. OBJECTIVES:The goal of this study was to investigate the role of ?1AR-AAbs belonging to the IgG3 subclass in patients with recent-onset cardiomyopathy. METHODS:Peripheral blood samples were drawn at enrollment in patients with recent-onset cardiomyopathy (left ventricular ejection fraction [LVEF] ?0.40; <6 months). The presence of IgG and IgG3-?1AR-AAb was determined, and echocardiograms were assessed, at baseline and 6 months. Patients were followed up for ?48 months. RESULTS:Among the 353 patients who had blood samples adequate for the analysis, 62 (18%) were positive for IgG3-?1AR-AAbs (IgG3 group), 58 (16%) were positive for IgG but not IgG3 (non-IgG3 group), and the remaining were negative. There were no significant differences in baseline systolic blood pressure, heart rate, or LVEF among the groups at baseline. Left ventricular end-diastolic and end-systolic diameters were significantly larger in the non-IgG3 group compared with the other groups (left ventricular end-diastolic diameter, p < 0.01; left ventricular end-systolic diameter, p = 0.03). At 6 months, LVEF was significantly higher in the IgG3 group (p = 0.007). Multiple regression analysis showed that IgG3-?1AR-AAb was an independent predictor of LVEF at 6 months and change in LVEF over 6 months, even after multivariable adjustment (LVEF at 6 months, ? = 0.20, p = 0.01; change in LVEF, ? = 0.20, p = 0.008). In patients with high New York Heart Association functional class (III or IV) at baseline, the IgG3 group had a lower incidence of the composite endpoint of all-cause death, cardiac transplantation, and hospitalization due to heart failure, whereas the non-IgG3 group had the highest incidence of the composite endpoint. CONCLUSIONS:IgG3-?1AR-AAbs were associated with more favorable myocardial recovery in patients with recent-onset cardiomyopathy.

SUBMITTER: Nagatomo Y 

PROVIDER: S-EPMC5330212 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β<sub>1</sub>-Adrenergic Receptors.

Nagatomo Yuji Y   McNamara Dennis M DM   Alexis Jeffrey D JD   Cooper Leslie T LT   Dec G William GW   Pauly Daniel F DF   Sheppard Richard R   Starling Randall C RC   Tang W H Wilson WH  

Journal of the American College of Cardiology 20170201 8


<h4>Background</h4>Among various cardiac autoantibodies (AAbs), those recognizing the β<sub>1</sub>-adrenergic receptor (β<sub>1</sub>AR) demonstrate agonist-like effects and induce myocardial damage that can be reversed by β-blockers and immunoglobulin G3 (IgG3) immunoadsorption.<h4>Objectives</h4>The goal of this study was to investigate the role of β<sub>1</sub>AR-AAbs belonging to the IgG3 subclass in patients with recent-onset cardiomyopathy.<h4>Methods</h4>Peripheral blood samples were dra  ...[more]

Similar Datasets

| S-EPMC7485715 | biostudies-literature
| S-EPMC7484403 | biostudies-literature
| S-EPMC5338268 | biostudies-literature
| S-EPMC7749461 | biostudies-literature
| S-EPMC9452444 | biostudies-literature
2023-05-24 | E-MTAB-12671 | biostudies-arrayexpress
| S-EPMC4394989 | biostudies-literature
| S-EPMC6800425 | biostudies-literature
| S-EPMC9276628 | biostudies-literature
| S-EPMC2588439 | biostudies-literature